In the Phase 3 TRIUMPH-1 trial reported May 21, 2026, the 12 mg arm produced mean body-weight reduction of 28.3% at 80 weeks, with extension data reaching 30.3% at 104 weeks [1][2]
Gout patients have a greater abundance of Bacteroides ( 85) along with decreased levels of Bifidobacterium and Lactobacillus ( Clostridium bacteria and Lactobacillus ( 86, 87), and hyperuricemic rats present decreased abundances of Lactobacillus , Streptococcus , and Clostridium ( 88)
Dual GLP-1/GIP) The main difference is the Dual-Agonist nature of Tirzepatide
Clinical Trial Status: Where Each Compound Stands in 2026 Tirzepatide (Fully Approved) Tirzepatide completed its regulatory journey and received: FDA approval as Mounjaro (2022) for type 2 diabetes management FDA approval as Zepbound (2023) for chronic weight management in adults with obesity or overweight with weight-related comorbidities It is available via prescription from licensed healthcare providers in the United States and many other countries
Aronne, director of the Comprehensive Weight Control Center and Sanford I
The key word remains "theoretically" since no study has specifically measured inflammatory markers in patients receiving injectable niacinamide alongside semaglutide
